Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
MHRA Approves Lower-Dose Needle-Free Adrenaline Spray for Younger Children
The UK regulator has authorised a 1 mg EURneffy nasal spray for children aged four and over who weigh 15 kg to 30 kg, extending needle-free emergency anaphylaxis treatment to a younger group.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The Medicines and Healthcare products Regulatory Agency has approved a lower-dose version of EURneffy, an adrenaline nasal spray for emergency treatment of serious allergic reactions in younger children.
The new 1 mg product is indicated for children aged four years and over who weigh between 15 kg and 30 kg. It extends access beyond the previously authorised 2 mg product for adults and children aged ten and above who weigh at least 30 kg.
MHRA says adrenaline remains a well-established emergency treatment for anaphylaxis and is intended for immediate self-administration at the first signs of a serious allergic reaction, before emergency help arrives.
The regulator emphasised that two doses must still be carried, because a second dose may be needed before an ambulance arrives. Emergency services should be called immediately after a dose is given.
Sourcing note: The age, weight range, dose and safety-monitoring statements are taken from the MHRA approval announcement. This article is not medical advice; patients and carers should follow prescribing information and clinician guidance.
Why It Matters
Needle-free adrenaline options may reduce barriers for some children, carers and school settings, but they do not remove the need for emergency planning. The practical impact will depend on prescribing guidance, availability, training and confidence in correct use during a high-stress allergic reaction.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
MHRAEURneffyAnaphylaxisAdrenalinePaediatric Medicine